Genetic landscape of congenital insensitivity to pain and hereditary sensory and autonomic neuropathies.
Annette LischkaKatja EggermannChristopher J RecordMaike F DohrnPetra LaššuthováFlorian KraftMatthias BegemannDaniela DeyEggermann ThomasDanique BeijerJana ŠoukalováMatilde LauraAlexander M RossorRadim MazanecJonas Van LentPedro José TomaselliMartin UngelenkKarlien Y DebusShawna M E FeelyDieter GläserSujatha JagadeeshMadelena MartinGeeta M GovindarajPratibha SinghiRevanth BaineniNiranjan BiswalMarisol Ibarra-RamírezMaryse BonduelleBurkhard GessJuan Romero SánchezRenu SutharVrajesh UdaniAtchayaram NaliniGopikrishnan UnnikrishnanWilson Marques JuniorSandra MercierVincent ProcaccioCéline BrisBeena SureshVaishnavi ReddyMariola SkorupinskaNathalie Bonello-PalotFanny MochelGeorg DahlKarthika SasidharanFiji M DevassikuttySheela NampoothiriMaria J Rodovalho DoriquiWolfgang Müller-FelberKatharina VillTobias B HaackAndreas DufkeMichael AbeleRolf StuckaSaima SiddiqiNoor UllahStephanie SprangerDeborah ChiabrandoBehiye S BolgülYesim ParmanPavel SeemanAngelika LampertJörg B SchulzJohn N WoodJames J CoxMichaela Auer-GrumbachVincent TimmermanJonathan de WinterAndreas C ThemistocleousMichael ShyDavid L H BennettJonathan BaetsChristian A HübnerEnrico LeipoldStephan ZüchnerMiriam ElbrachtArman ÇakarJan SenderekThorsten HornemannC Geoffrey WoodsMary M ReillyIngo KurthPublished in: Brain : a journal of neurology (2023)
Congenital insensitivity to pain (CIP) and hereditary sensory and autonomic neuropathies (HSAN) are clinically and genetically heterogeneous disorders exclusively or predominantly affecting the sensory and autonomic neurons. Due to the rarity of the diseases and findings based mainly on single case reports or small case series, knowledge about these disorders is limited. Here, we describe the molecular workup of a large international cohort of CIP/HSAN patients including patients from normally underrepresented countries. We identify 80 previously unreported pathogenic or likely pathogenic variants in a total of 73 families in the >20 known CIP/HSAN-associated genes. The data expand the spectrum of disease-relevant alterations in CIP/HSAN, including novel variants in previously rarely recognised entities such as ATL3-, FLVCR1- and NGF-associated neuropathies and previously under-recognised mutation types such as larger deletions. In silico predictions, heterologous expression studies, segregation analyses and metabolic tests helped to overcome limitations of current variant classification schemes that often fail to categorize a variant as disease-related or benign. The study sheds light on the genetic causes and disease-relevant changes within individual genes in CIP/HSAN. This is becoming increasingly important with emerging clinical trials investigating subtype or gene-specific treatment strategies.
Keyphrases
- genome wide
- end stage renal disease
- copy number
- clinical trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- chronic pain
- spinal cord
- heart rate
- prognostic factors
- neuropathic pain
- deep learning
- machine learning
- patient reported outcomes
- peritoneal dialysis
- gene expression
- poor prognosis
- molecular docking
- blood pressure
- growth factor
- artificial intelligence
- open label
- patient reported
- phase ii
- data analysis
- molecular dynamics simulations